

	Pilot Trial n=20	Phase II trial n=41	p-value for difference between two study groups
Median age (range)	45y (8-63y)	45y (7-65y)	0.99
Myeloablative conditioning	80%	51%	0.11
Unrelated donor	30%	32%	0.47
Mismatched	5%	17%	0.19
GVHD at start of treatment			
Grade 2	70%	66%	0.75
Grade 3-4	30%	34%	
Skin	70%	56%	0.30
Liver	20%	12%	0.42
GI	55%	63%	0.42